What does the FDA's July 2026 peptide vote actually mean?

It is a nonbinding recommendation from an advisory committee, not a legalization. Six of the seven peptides reviewed were recommended favorably; the FDA still has to issue a formal determination before any of them can legally be compounded.

Where can I legally get peptide therapy today?

Through a licensed provider who prescribes via a 503A or 503B compounding pharmacy, or through an FDA-approved drug such as semaglutide or tirzepatide. Research-use-only suppliers are not a legal channel for human use.

Does removal from the FDA's restricted list mean a peptide is safe?

No. Removal from the restricted list is not the same as being tested and approved. Compounded medications are still not independently verified for safety and quality the way FDA-approved drugs are.

Regulatory status · Updated as it changes

Six peptides just cleared a major FDA hurdle. None of them are legal to compound yet.

Q: Is BPC-157 legal in the US right now?

Not yet. On July 23, 2026 an FDA advisory committee recommended it for legal compounding, but the FDA has not issued a final determination. Licensed pharmacies cannot legally compound it until that happens.

On July 23–24, 2026, an FDA advisory committee recommended BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for the federal compounding list. That's real progress. It's not approval. Here's what actually changed, and what's still just talk.

Primary-source only · FDA status tracked · Not a pharmacy

We're not a clinical or legal practice — our background is behavioral health technology and operations. This tracker follows FDA public actions directly. Confirm specifics with a licensed provider.

Are Peptides Legal in the US in 2026? Quick Answers

The short version of everything below, in case that's all you need.

Is BPC-157 legal in the US right now?

Not yet. An FDA advisory committee recommended it for compounding on July 23, 2026, but the FDA hasn't issued a final determination. Pharmacies still can't legally compound it.

What did the FDA's July 2026 vote actually decide?

Nothing, yet. It's a nonbinding advisory recommendation. Six of seven reviewed peptides were recommended favorably; a formal FDA determination is still pending.

Where can I get peptide therapy legally today?

Through a licensed provider prescribing via a 503A/503B compounding pharmacy, or an FDA-approved drug like semaglutide or tirzepatide. Research-use suppliers aren't a legal channel for human use.

Can I get retatrutide legally right now?

No. Retatrutide isn't FDA-approved, so it can't be legally compounded — a clinical trial is the only legitimate access. Approved GLP-1s like semaglutide and tirzepatide are the legal option today. Retatrutide isn't expected before 2027.

Does "no longer restricted" mean a peptide is safe?

No. It means the FDA is reconsidering it, not that it's been tested and approved. Quality and dosing still vary between pharmacies.

The docket

Every step that got us here, in order. We update this whenever something changes.

Sept 2023

Category 2 listingFDA places BPC-157 and TB-500 on its restricted list, barring US compounding pharmacies from producing them.
2024–2025

Enforcement widensWarning letters and account shutdowns hit noncompliant compounders and unlicensed sellers across the category.
Feb 27, 2026

HHS signals a reversalFederal health officials publicly acknowledge the restrictions had been pushing patients toward the unregulated gray market.
Apr 22, 2026

Twelve peptides freed for reviewFDA removes them from Category 2. That's a door opening, not a legalization.
Jul 23–24, 2026

Advisory committee votesSeven peptides reviewed for the 503A Bulks List. Six recommended favorably; one — emideltide (DSIP) — was not.
Pending

Formal FDA determinationThe committee's vote is nonbinding. A final agency decision and rulemaking process are still ahead. GHK-Cu and others go to a later session before Feb 2027.

Which Peptides Can Be Legally Compounded in 2026?

Nothing here is approved for over-the-counter use. This is where each substance sits in the federal process today.

Recommended by the committee (6) Not recommended (1)

Status reflects the most recent FDA Pharmacy Compounding Advisory Committee action as of the verification date above.
Compound	Committee action	Current channel	Status
BPC-157	Recommended, Jul 23 '26	Not yet compoundable — a provider can review what’s available now	Under review
KPV	Recommended, Jul 23 '26	Not yet compoundable — a provider can review what’s available now	Under review
TB-500	Recommended, Jul 23 '26	Not yet compoundable — a provider can review what’s available now	Under review
MOTS-c	Recommended, Jul 23 '26	Not yet compoundable — a provider can review what’s available now	Under review
Epitalon	Recommended, Jul 24 '26	Not yet compoundable — a provider can review what’s available now	Under review
Semax	Recommended, Jul 24 '26	Not yet compoundable — a provider can review what’s available now	Under review
Emideltide (DSIP)	Not recommended, Jul 24 '26	Remains restricted	Restricted
Semaglutide / Tirzepatide / Tesamorelin	N/A — already approved	FDA-approved. A licensed provider can assess your eligibility and prescribe.	Approved

GLP-1s: semaglutide, tirzepatide, and the retatrutide question

This is the most-searched corner of the category, and the most misunderstood. The three are in very different legal positions.

GLP-1 legal status as of the verification date above. Shortage and compounding rules here have moved through the courts and change more often than the peptide list.
Drug	Approval	Legal channel today	Status
Semaglutide Wegovy, Ozempic	FDA-approved	Approved and prescribable today — a licensed provider can assess whether it's appropriate for you, including for weight management. Compounded versions also reach patients via 503A pharmacies under ongoing legal challenges.	Approved
Tirzepatide Zepbound, Mounjaro	FDA-approved	Approved and prescribable today — same as semaglutide, a provider can evaluate your eligibility. Compounded access continues under contested rules after shortage removal.	Approved
Retatrutide investigational triple agonist	Not approved	No legal channel yet — never approved, so it can't be compounded, and the only legitimate access is an enrolling clinical trial. If you're after the results retatrutide is known for, a provider can evaluate you for an approved GLP-1 available now.	No legal route

Why retatrutide is different from semaglutide during the shortage. Compounding is only permitted under specific conditions. An approved version of the drug existing is one of them. Semaglutide and tirzepatide qualified during their shortages because approved brands (Wegovy, Zepbound) exist. Retatrutide has never been approved in any form, so no compounding pathway applies, and the FDA has issued warning letters to sellers marketing "compounded retatrutide."

Anything sold online as "retatrutide" today comes from an unregulated source with no quality control. If weight loss is the goal, the two approved GLP-1s are the legitimate near-term options while retatrutide moves through its trials. Approval is generally expected no earlier than 2027.

Ready to see if an approved option fits you? Get matched with a licensed provider →

What a favorable vote does not mean

A committee recommendation is not a legalization. Compounding pharmacies still can't legally produce these substances until the FDA issues a formal determination. That process has historically taken months.

Even once compounding resumes, "eligible for compounding" is not the same as "FDA-approved and proven safe." Compounded medications aren't independently tested the way manufactured drugs are, and quality can still vary between pharmacies. Confirm current status with a licensed provider before assuming anything below is settled.

Three ways people get these — only two involve a doctor

FDA-approved prescription

Tightest oversight. Pharmacy-dispensed, sometimes insurance-eligible. Applies to semaglutide, tirzepatide, tesamorelin and similar approved drugs.

Licensed compounding pharmacy, by prescription

A provider evaluates you, then a 503A or 503B pharmacy prepares the compound. This is the legitimate channel for everything else on this page. It's the one we point people toward.

"Research use only" suppliers

No prescriber, no consistent testing, not regulated as a drug. This page doesn't track or link to this channel.

State rules vary, and they matter. State law can differ from the federal picture above. Florida, for example, has moved independently to preserve compounding access even as federal rules tighten elsewhere. Other states have their own rules too. Wherever you are, the federal status above isn't the final word for you. Get matched with a licensed provider in your state.

Get matched with a licensed provider

Tell us what you're looking into. We'll point you to a provider that runs real clinical evaluation and works with licensed US compounding pharmacies. Not a research-chem supplier.